Purchase of pharmaceuticals which treat the underlying cause of cystic fibrosis (CFTR modulators)

Informasjon

15 - Intensjonskunngjøring
Veiledende kunngjøring - ikke konkurranse
04.10.2018 09.18 (GMT+02:00)

Innkjøper

Amgros I/S Amgros I/S
Jon Bjergfelt Jon Bjergfelt
Dampfærgevej 22
2100 København Ø
Danmark

Tildelingsinformasjon

Cystic fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is caused by the presence of mutations in both copies of the gene for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein. Today, patients with cystic fibrosis are mainly treated with pharmaceuticals which reduce the symptoms of cystic fibrosis without treating their underlying cause. Amgros wishes to enter into a contract ensuring that public hospitals in Denmark, Greenland and the Faroe Islands will be able to offer all their cystic fibrosis patients treatment with pharmaceuticals, which treat the underlying cause of cystic fibrosis (CFTR modulators).

Mercell Norge AS

Del av Mercell-gruppen, en av Europas ledende leverandører av elektroniske anbudsverktøy og informasjon mellom innkjøpere og leverandører i det profesjonelle markedet.

Kontakt oss

Klikk her for å gå til support

+47 21 01 88 00